

Tryptin®

Amitriptyline

Antidepressant

COMPOSITION

Tryptin® 10 tablet : Each film coated tablet contains Amitriptyline hydrochloride USP 10 mg

Tryptin® 25 tablet : Each film coated tablet contains Amitriptyline hydrochloride USP 25 mg.

PHARMACOLOGY

Tryptin® (amitriptylin) is a tricyclic antidepressant. It has marked anticholinergic and sedative properties. It prevents the reuptake of noradrenaline and serotonin at nerve ending. Amitriptyline hydrochloride is rapidly absorbed from the G.I. tract. Peak plasma concentrations occur within 2-12 hours. Amitriptyline is excreted in the urine, mainly in the form of its metabolites .

INDICATION

Tryptin® is indicated for depressive illness, particularly with anxiety and nocturnal enuresis in children.

DOSAGE AND ADMINISTRATION

Depression :

Adults: Initially 50-70 mg a day in divided dose or as a single dose at night at bed time. For elderly patients and adolescents 25-50 mg daily in divided doses or as single dose at bed time.

Dose can be increased gradually as necessary to a maximum of 150-200 mg. Usual maintenance dose is 50-100 mg daily.

Nocturnal enuresis :

6-10 years: 10-20 mg at bed time.

11-16 years: 25-50 mg at bed time for up to 3 months and gradually withdrawn.

CONTRAINDICATION AND PRECAUTION

Amitryptin® is contraindicated in myocardial infarction; arrythmias, particularly heartblock of any degree; mania; severe liver disease.

Initially sedation may effect the ability to drive or operate machinery. It should be used with caution in patients with a history of epilepsy, glaucoma, urinary retention, prostatic hypertrophy, constipation, cardiac disease, diabetes, pregnancy, hepatic impairment, thyroid disease, increased intra-occular pressure, psychoses (may aggravate mania).

SIDE EFFECT

Cardiovascular reactions: Hypotension, syncope, postural hypotension, hypertension, tachycardia, palpitations, myocardial infarction, arrythmias, and heart block stroke.

CNS and neuromuscular: Confusional states, disturbed concentration disorientation, delusions, and hallucinations.

Anticholinergic: Dry mouth, blurred vision, mydriasis, increased intraoccular pressure, hyperplasia.

Allergic: Skin rash, urticaria, and photosensitization.

Haematological: Bone-marrow depression including agranulocytosis, leukopenia, eosinophilia, and thrombocytopenia.

Gastrointestinal: Nausea, epigastric distress, vomiting anorexia, diarrhoea.

Endocrine: Testicular swelling, gynaecomastia; breast enlargement, galactorrhoea.

Other reaction: Dizziness, weakness, fatigue, headache, weight loss.

DRUG INTERACTION

Monoamine oxidase inhibitors can potentiate the effects of Amitryptin®.

Anticholinergic agents: Amitriptylin should not be given with symptomatic agents such as adrenaline, epinephrine, isoprenaline, noradrenaline.

CNS depressant: Amitryptin® may enhance the response to alcohol, barbiturates.

Cemitidine: Cemitidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants.

USE IN PREGNANCY AND LACTATION

Amitryptin® is not recommended during pregnancy, especially during the first and third trimester because the safety of Amitryptin® has not been established yet. Amitriptyline is detectable in breast milk. Because of the serious adverse reactions in infants from amitriptyline, a decision should be made whether to continue breast feeding or discontinue the drug.

STORAGE CONDITION

Keep containers well closed and stored below 25˚C, protected from light.

HOW SUPPLIED

Tryptin® 10 tablet: Box containing 20 x 10 film coated tablets in strip pack.
Tryptin® 25 tablet: Box containing 20 x 10 film coated tablets in strip pack.